Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/24211
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHall, S.-
dc.contributor.authorMease, P.-
dc.contributor.authorKavanaugh, A.-
dc.contributor.authorReimold, A.-
dc.contributor.authorTahir, H.-
dc.contributor.authorRech, J.-
dc.contributor.authorGEUSENS, Piet-
dc.contributor.authorPascale, P.-
dc.contributor.authorDelicha, E.-
dc.contributor.authorPricop, L.-
dc.contributor.authorMpofu, S.-
dc.date.accessioned2017-08-11T10:22:47Z-
dc.date.available2017-08-11T10:22:47Z-
dc.date.issued2017-
dc.identifier.citationINTERNAL MEDICINE JOURNAL, 47, p. 37-38 (Art N° P90)-
dc.identifier.issn1444-0903-
dc.identifier.urihttp://hdl.handle.net/1942/24211-
dc.description.abstractSecukinumab, an anti–interleukin-17A monoclonal antibody, provided rapid and significant improvements in the key clinical domains of psoriatic arthritis (PsA) in the FUTURE 1 study (NCT01392326) with improvements sustained through 2 years. Here, we present efficacy and safety results through 3 years in the extension of the FUTURE 1 study.-
dc.language.isoen-
dc.publisherWILEY-
dc.titleSecukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis (PSA) through 3 years: efficacy and safety results from a phase 3 trial-
dc.typeJournal Contribution-
dc.identifier.epage38-
dc.identifier.spage37-
dc.identifier.volume47-
local.format.pages2-
local.bibliographicCitation.jcatM-
dc.description.notes[Hall, S.] Monash Univ, Melbourne, Vic, Australia. [Mease, P.] Swedish Med Ctr, Seattle, WA USA. [Mease, P.] Univ Washington, Seattle, WA 98195 USA. [Kavanaugh, A.] Univ Calif San Diego, Sch Med, La Jolla, CA USA. [Reimold, A.] Dallas VA Med Ctr, Dallas, TX USA. [Reimold, A.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. [Tahir, H.] Barts Hlth NHS Trust, London, England. [Rech, J.] Friedrich Alexander Univ Erlangen Narnberg Fau, Univ Klinikum Erlangen, Dept Internal Med Rheumatol & Immunol, Erlangen, Germany. [Geusens, P.] Univ Hasselt, Hasselt, Belgium. [Geusens, P.] Maastricht Univ Hosp, Maastricht, Netherlands. [Pascale, P.; Delicha, E.; Mpofu, S.] Novartis Pharma Ag, Basel, Switzerland. [Pricop, L.] Novartis Pharmaceut, E Hanover, NJ USA.-
local.publisher.placeHOBOKEN-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
local.bibliographicCitation.artnrP90-
dc.identifier.isi000400304400113-
dc.identifier.urlhttp://acrabstracts.org/abstract/secukinumab-provides-sustained-improvements-in-the-signs-and-symptoms-of-active-psoriatic-arthritis-through-3-years-efficacy-and-safety-results-from-a-phase-3-trial/-
item.accessRightsOpen Access-
item.fullcitationHall, S.; Mease, P.; Kavanaugh, A.; Reimold, A.; Tahir, H.; Rech, J.; GEUSENS, Piet; Pascale, P.; Delicha, E.; Pricop, L. & Mpofu, S. (2017) Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis (PSA) through 3 years: efficacy and safety results from a phase 3 trial. In: INTERNAL MEDICINE JOURNAL, 47, p. 37-38 (Art N° P90).-
item.fulltextWith Fulltext-
item.contributorHall, S.-
item.contributorMease, P.-
item.contributorKavanaugh, A.-
item.contributorReimold, A.-
item.contributorTahir, H.-
item.contributorRech, J.-
item.contributorGEUSENS, Piet-
item.contributorPascale, P.-
item.contributorDelicha, E.-
item.contributorPricop, L.-
item.contributorMpofu, S.-
crisitem.journal.issn1444-0903-
crisitem.journal.eissn1445-5994-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
acrabstracts_org_abstract_secukinumab_provides_sustained_imp.pdfPublished version65.7 kBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.